Minoryx Therapeutics and Neuraxpharm Group have announced a significant breakthrough in the treatment of cerebral adrenoleukodystrophy (cALD) in paediatric...
Read MoreBayer has officially begun a Phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor designed to...
Read MoreEverest Medicines has announced groundbreaking results from its Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine kinase...
Read MoreTeva Pharmaceutical Industries has unveiled encouraging results from its Phase 3 SPACE study, highlighting the efficacy and safety of...
Read MoreA groundbreaking new treatment for asthma and chronic obstructive pulmonary disease (COPD) could revolutionise how these life-threatening conditions are...
Read MoreIn a significant milestone for autoimmune disease research, argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative...
Read More